Frexalimab Study for Multiple Sclerosis: This study is testing a new medicine called frexalimab for adults with relapsing forms of multiple sclerosis (MS). MS is a disease where the immune system attacks the nervous system. The study will compare frexalimab to another medicine called teriflunomide.

Key Study Details:

• The study could last between 12 to 40 months for each person, depending on when they join.
• You will need to visit the study location every 4 weeks for the first 6 months, then every 3 months.
• The study is open to adults aged 18-55 with relapsing MS who meet specific health criteria.

Eligibility: You should have had at least one MS relapse in the last year or specific MRI findings. People with primary progressive MS, certain infections, or other health conditions may not join. Men and women must follow local rules for contraception during the study.

This study helps doctors learn more about frexalimab and if it works better than current treatments. Please think carefully about the time commitment and visit schedule before deciding to participate.